SCHEDULE 13G 0001595855 XXXXXXXX LIVE Common Stock, no par value 10/10/2025 0001503802 Karyopharm Therapeutics Inc. 48576U205 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 Rule 13d-1(c) Opaleye Management Inc. MA 0.00 1569002.00 0.00 1569002.00 1569002.00 N 9.48 IA CO Opaleye, L.P. MA 0.00 1569002.00 0.00 1569002.00 1569002.00 N 9.48 PN Based on a statement in the Current Report on Form 8-K, as filed by Karyopharm Therapeutics Inc. with the Securities and Exchange Commission on October 8, 2025, that the issuer expects to have 15,926,939 shares of common stock outstanding following consummation of the transactions described therein. James Silverman X1 0.00 1569002.00 0.00 1569002.00 1569002.00 N 9.48 IN Karyopharm Therapeutics Inc. 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459 Opaleye Management Inc. Opaleye, L.P. James Silverman This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to shares directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the shares reported herein. One Boston Place, 26th Floor, Boston, MA 02108 Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Massachusetts James Silverman - USA Y As of October 10, 2025, the Fund beneficially owned an aggregate of 1,569,002 shares of Common Stock of the Issuer, including 619,089 issuable upon exercise of warrants (the "Warrants") that are immediately exercisable. Beneficial ownership percentages reported herein are based on a statement in the Current Report on Form 8-K, as filed by Karyopharm Therapeutics Inc. with the Securities and Exchange Commission on October 8, 2025, that the issuer expects to have 15,926,939 shares of common stock outstanding following consummation of the transactions described therein. 9.48 % 0 1,569,002.00 0 1,569,002.00 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement by and among the reporting persons Opaleye Management Inc. /s/ James Silverman 10/17/2025 Opaleye, L.P. /s/ James Silverman 10/17/2025 James Silverman /s/ James Silverman 10/17/2025